<DOC>
	<DOCNO>NCT03052413</DOCNO>
	<brief_summary>The objective study assess safety effectiveness nutraceutical supplement treatment hair loss thin female course six month continuous daily use .</brief_summary>
	<brief_title>Study Evaluate Nutraceutical Supplement Treatment Hair Loss Thinning Females</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , study adult female subject mild moderate hair loss . Following 35-day screening period determine eligibility , subject randomly assign one follow treatment arm : Nutrafol® v . Placebo . Nutrafol® Placebo randomly assign administered daily subject 6 month start Day 2 . The subject return study site Day 90 Day 180 assessment . Additionally , subject return study site approximately 48 hour Day 0 ( Baseline Visit ) D180 order ass hair growth rate . Nutrafol® Placebo dispense non-blinded study staff nonlabeled container contain correspond tablet . Efficacy rating perform trained investigator aware subject 's treatment randomization order preserve double-blinding study .</detailed_description>
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<criteria>1 . Females 21 55 year age , inclusive 2 . Skin type IIV 3 . Have selfreported thin hair loss 6 month prior screen 4 . Clinically confirm hair loss thin investigator via physical exam , include subject female pattern hair loss Savin Classification score I2II1 determine investigator ( medical history , physical exam /or strong family history hair loss define 2 relative know similar Savin pattern loss without diagnosed disease ) 5 . In good general health , determine Investigator 6 . Willing able attend study visit 7 . Willing maintain hair style Screening Visit duration study . If color hair , willing color frequency usage past , make sure color within 3 week inoffice appointment . 8 . Willing use mild nonmedicated shampoo conditioner duration study ( medicate shampoo conditioner refer prescription shampoo conditioner well overthe counter medicate shampoo conditioner , treatment dandruff promote hair growth ) 9 . Willing hair clip scalp tattoo 10 . Have negative urine pregnancy test screen use , continue use duration study , effective contraception method ( ie , abstinence , barrier control , intrauterine device [ IUD ] , hormonal [ estrogen/progestin ] contraceptive ) least one menstrual cycle prior study ; use IUD hormonal contraceptive least 2 year prior screen , initiation associate initiation hair loss/thinning . 11 . Be willing able cooperate requirement study . 12 . Voluntarily sign date inform consent agreement approve Institutional Review Board . 13 . Be able complete understand various rating instrument English . 14 . Sponsor approve global image assessment degree thin / hair loss 1 . Clinical diagnosis alopecia areata scar form alopecia 2 . Scalp hair loss treatment area , due disease , injury , medical therapy 3 . Subjects pregnant , plan become pregnant breastfeeding . A urine pregnancy test do rule pregnancy , Subjects childbearing potential use approved method birth control ( oral contraceptive , IUD , contraceptive implant , barrier method spermicide abstinence ) . Females nonchildbearing potential define postmenopausal ( absence menstrual bleed one year ) , hysterectomy bilateral oophorectomy . 4 . Current skin disease ( e.g. , psoriasis , atopic dermatitis , skin cancer , eczema , sun damage , seborrheic dermatitis ) , cuts abrasion scalp condition ( e.g. , sunburn , tattoo ) treatment area , opinion Investigator , might put subject risk interfere study conduct evaluation . 5 . History surgical correction hair loss scalp/ Hair transplant . 6 . Use product device purport promote scalp hair growth ( e.g. , finasteride minoxidil ) within 30 day prior Baseline Visit . 7 . Use antiandrogenic therapy ( e.g. , spironolactone , flutamide , cyproterone acetate , cimetidine ) within 30 day prior Baseline Visit . 8 . No history burning , flaking , itching , sting scalp . 9 . History malignancy ( except scc bcc skin cancer ) undergo chemotherapy radiation treatment . 10 . A known history autoimmune thyroid disease , thyroid disorder/abnormality autoimmune disorder opinion investigator may interfere study treatment . 11 . A known history depression bipolar disease condition may impact subject 's participation . 12 . Subjects take vitamin E supplement participate , provide medication interrupt 14 day baseline visit . 13 . Recent utilization low level laser . 14 . Has condition treat investigator PI think may put Subject risk interfere participation study . 15 . Is involved injury litigation claim 16 . Known history recent bloodwork indicate iron deficiency , bleed disorder platelet dysfunction syndrome well subject receive anticoagulant therapy smoker usage &gt; 20 cigarettes/day . 17 . Use medication know potentially cause hair loss affect hair growth , determine PI .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>thin hair</keyword>
	<keyword>female pattern hair loss</keyword>
</DOC>